Balyasny Asset Management LLC Viking Therapeutics, Inc. Transaction History

Balyasny Asset Management LLC

$57.8 Billion
Q1 2025

A detailed history of Balyasny Asset Management LLC transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Balyasny Asset Management LLC holds 15,300 shares of VKTX stock, worth $491,130. This represents 0.0% of its overall portfolio holdings.

Number of Shares

15,300

Previous 25,000 38.8%

Holding current value

$491,130

Previous $1.01 Million 63.32%

% of portfolio

0.0%

Previous 0.0%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$24.15 - $42.89 $19 Million - $33.8 Million	788,179 Added 91.6%	1,648,628 $39.8 Million
Q4 2024 Feb 14, 2025	BUY	$38.28 - $78.03 $32.9 Million - $67.1 Million	860,449 New	860,449 $34.6 Million
Q2 2024 Aug 14, 2024	BUY	$47.39 - $80.2 $3.64 Million - $6.16 Million	76,787 Added 70.71%	185,382 $9.83 Million
Q1 2024 May 13, 2024	SELL	$17.4 - $94.5 $37.1 Million - $202 Million	-2,134,928 Reduced 95.16%	108,595 $8.9 Million
Q4 2023 Feb 14, 2024	BUY	$9.24 - $19.64 $1.12 Million - $2.39 Million	121,624 Added 5.73%	2,243,523 $41.8 Million
Q3 2023 Nov 14, 2023	BUY	$10.92 - $16.0 $16.5 Million - $24.1 Million	1,506,631 Added 244.87%	2,121,899 $23.5 Million
Q2 2023 Aug 14, 2023	BUY	$14.84 - $24.79 $870,529 - $1.45 Million	58,661 Added 10.54%	615,268 $9.97 Million
Q1 2023 May 15, 2023	BUY	$8.08 - $17.33 $3.66 Million - $7.85 Million	452,837 Added 436.39%	556,607 $9.27 Million
Q4 2022 Feb 14, 2023	SELL	$2.72 - $9.4 $6.99 Million - $24.2 Million	-2,569,794 Reduced 96.12%	103,770 $975,000
Q3 2022 Nov 14, 2022	BUY	$2.55 - $3.89 $78,063 - $119,084	30,613 Added 1.16%	2,673,564 $7.27 Million
Q2 2022 Aug 15, 2022	BUY	$2.11 - $3.15 $5.58 Million - $8.33 Million	2,642,951 New	2,642,951 $7.64 Million
Q3 2020 Nov 16, 2020	SELL	$5.73 - $8.11 $59,649 - $84,425	-10,410 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$4.35 - $8.08 $45,283 - $84,112	10,410 New	10,410 $75,000
Q4 2019 Feb 14, 2020	SELL	$6.38 - $8.73 $65,363 - $89,438	-10,245 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$6.55 - $8.6 $53,926 - $70,803	-8,233 Reduced 44.56%	10,245 $70,000
Q2 2019 Aug 14, 2019	SELL	$7.67 - $10.63 $331,190 - $459,003	-43,180 Reduced 70.03%	18,478 $153,000
Q1 2019 May 15, 2019	SELL	$7.58 - $9.94 $2.29 Million - $3 Million	-301,948 Reduced 83.04%	61,658 $613,000
Q4 2018 Feb 14, 2019	SELL	$7.16 - $16.21 $5.24 Million - $11.9 Million	-731,245 Reduced 66.79%	363,606 $2.78 Million
Q3 2018 Nov 14, 2018	BUY	$9.7 - $19.65 $8.15 Million - $16.5 Million	839,851 Added 329.35%	1,094,851 $19.1 Million
Q2 2018 Aug 14, 2018	BUY	$3.88 - $12.74 $989,400 - $3.25 Million	255,000 New	255,000 $2.42 Million

Others Institutions Holding VKTX

# of Institutions

447

Shares Held

65.4M

Call Options Held

8.28M

Put Options Held

3.39M

View Full List

About Viking Therapeutics, Inc.

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $2.46B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

More about VKTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Balyasny Asset Management LLC with notifications on news.

Account

Balyasny Asset Management LLC Viking Therapeutics, Inc. Transaction History